Cagrilintide Research Peptide Information Peptpedia Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Novo Nordisk files for FDA approval of CagriSema, the first once weekly combination of GLP1 and amylin analogues for weight management The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies